Raloxifene prevents endothelial dysfunction in aging ovariectomized female rats

Vascular Pharmacology

Volumn 44, Issue 5, 2006, Pages 290-298

  Wong, Chi Ming ^a   Yao, Xiaoqiang ^a   Au, Chak Leung ^a   Tsang, Suk Ying ^a   Fung, Kwok Pui ^a   Laher, Ismail ^b   Vanhoutte, Paul M ^c   Huang, Yu ^a  

^a CHINESE UNIVERSITY OF HONG KONG   (Hong Kong)

^b UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^c UNIVERSITY OF HONG KONG   (Hong Kong)

Author keywords

Arteries; Endothelial function; Hormones; Vasoconstriction dilation

Indexed keywords

1H 1,2,4 OXADIAZOLO[4,3 A]QUINOXALIN 1 ONE; ACETYLCHOLINE; CYCLIC GMP; ENDOTHELIAL NITRIC OXIDE SYNTHASE; N(G) NITROARGININE METHYL ESTER; NITRIC OXIDE; PHENYLEPHRINE; RALOXIFENE; THAPSIGARGIN;

AGING; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTERY CONSTRICTION; ARTICLE; BLOOD VESSEL REACTIVITY; CONTROLLED STUDY; ENDOTHELIAL DYSFUNCTION; FEMALE; NONHUMAN; OVARIECTOMY; PRIORITY JOURNAL; PROTEIN EXPRESSION; RAT; VASCULAR ENDOTHELIUM; VASCULAR RING;

ACETYLCHOLINE; AGING; ANIMALS; AORTA, THORACIC; BONE DENSITY CONSERVATION AGENTS; CALCIUM CHLORIDE; DOSE-RESPONSE RELATIONSHIP, DRUG; ENDOTHELIUM, VASCULAR; FEMALE; NITRIC OXIDE; NITRIC OXIDE SYNTHASE TYPE III; OVARIECTOMY; PHENYLEPHRINE; RALOXIFENE; RATS; RATS, SPRAGUE-DAWLEY; VASOCONSTRICTION; VASOCONSTRICTOR AGENTS; VASODILATION; VASODILATOR AGENTS;

EID: 33646124946     PISSN: 15371891     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.vph.2005.12.005     Document Type: Article

References (25)

1. Barrett-Connor E., and Bush T.L. Estrogen and coronary heart disease in women. JAMA 265 (1991) 1861-1867
2. Couzin J. Estrogen research. The great estrogen conundrum. Science 302 (2003) 1136-1138
3. Delmas P.D., Bjarnason N.H., Mitlak B.H., Ravoux A.C., Shah A.S., Huster W.J., Draper M., and Christiansen C. Effects of raloxifene on bone mineral density, serum cholesterol concentrations, and uterine endometrium in postmenopausal women. N. Engl. J. Med. 337 (1997) 1641-1647
4. Fortepiani L.A., Zhang H., Racusen L., Roberts II L.J., and Reckelhoff J.F. Characterization of an animal model of postmenopausal hypertension in spontaneously hypertensive rats. Hypertension 4 (2003) 640-645
5. Ganz P. Vasomotor and vascular effects of hormone replacement therapy. Am. J. Cardiol. 90 (2002) 11F-16F (Suppl)
6. Hayashi T., Fukuto J.M., Ignarro L.J., and Chaudhuri G. Basal release of nitric oxide from aortic rings is greater in female rabbits than in male rabbits: implications for atherosclerosis. Proc. Natl. Acad. Sci. U. S. A. 89 (1992) 11259-11263
7. Hulley S., Grady D., Bush T., Furberg C., Herrington D., Riggs B., and Vittinghoff E. Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women. JAMA 280 (1998) 605-613
8. Lidor A.L., Cohen S.B., Seidman D.S., Novikov I., Rabinovici J., Mashiach S., and Lipitz S. Effect of raloxifene on the ovarian circulation in women after menopause. Am. J. Obstet. Gynecol. 186 (2002) 984-989
9. McDonnell D.P. The molecular pharmacology of SERMs. Trends Endocrinol. Metab. 10 (1999) 301-311
10. Moien-Afshari F., Kenyon E., Choy J.C., Battistini B., McManus B.M., and Laher I. Long-term effects of ovariectomy and estrogen replacement treatment on endothelial function in mature rats. Maturitas 45 (2003) 213-223
11. Paganini-Hill A., Ross R.K., and Henderson B.E. Postmenopausal oestrogen treatment and stroke: a prospective study. BMJ 297 (1988) 519-522
12. Pavo I., Laszlo F., Morschl E., Nemcsik J., Berko A., Cox D.A., and Laszlo F.A. Raloxifene, an oestrogen-receptor modulator, prevents decreased constitutive nitric oxide and vasoconstriction in ovariectomized rats. Eur. J. Pharmacol. 410 (2000) 101-104
13. Rahimian R., Dube G.P., Toma W., Dos Santos N., McManus B.M., and van Breemen C. Raloxifene enhances nitric oxide release in rat aorta via increasing endothelial nitric oxide mRNA expression. Eur. J. Pharmacol. 434 (2002) 141-149
14. Riggs B.L., and Hartmann L.C. Selective estrogen-receptor modulators-mechanisms of action and application to clinical practice. N. Engl. J. Med. 348 (2003) 618-629
15. Rossouw J.E., Anderson G.L., Prentice R.L., LaCroix A.Z., Kooperberg C., Stefanick M.L., Jackson R.D., Beresford S.A., Howard B.V., Johnson K.C., Kotchen J.M., and Ockene J. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women's Health Initiative randomized controlled trial. JAMA 288 (2002) 321-333
16. Saitta A., Altavilla D., Cucinotta D., Morabito N., Frisina N., Corrado F., D'Anna R., Lasco A., Squadrito G., Gaudio A., Cancellieri F., Arcoraci V., and Squadrito F. Randomized, double-blind, placebo-controlled study on effects of raloxifene and hormone replacement therapy on plasma no concentrations, endothelin-1 levels, and endothelium-dependent vasodilation in postmenopausal women. Arterioscler. Thromb. Vasc. Biol. 21 (2001) 1512-1519
17. Simoncini T., Genazzani A.R., and Liao J.K. Nongenomic mechanisms of endothelial nitric oxide synthase activation by the selective estrogen receptor modulator raloxifene. Circulation 105 (2002) 1368-1373
18. Smith A.R., and Hagen T.M. Vascular endothelial dysfunction in aging: loss of Akt-dependent endothelial nitric oxide synthase phosphorylation and partial restoration by (R)-α-lipoic acid. Biochem. Soc. Trans. 31 (2003) 1447-1449
19. Stampfer M.J., Colditz G.A., Willet W.C., Manson J.E., Rosner B., Speizer F.E., and Hennekens C.H. Postmenopausal estrogen therapy and cardiovascular disease. N. Engl. J. Med. 325 (1991) 756-762
20. Teede H., van der Zypp A., and Majewski H. Gender differences in protein kinase G-mediated vasorelaxation of rat aorta. Clin. Sci. (Lond.) 100 (2001) 473-479
21. Thorin E., Pham-Dang M., Clement R., Mercier I., and Calderone A. Hyper-reactivity of cerebral arteries from ovariectomized rats: therapeutic benefit of tamoxifen. Br. J. Pharmacol. 140 (2003) 1187-1192
22. Vanhoutte P.M. Endothelial dysfunction and atherosclerosis. Eur. Heart J. 18 Suppl E (1997) 19-29
23. Vanhoutte P.M., Feletou M., and Taddei S. Endothelium-dependent contractions in hypertension. Br. J. Pharmacol. 144 (2005) 449-458
24. Wassmann S., Laufs U., Stamenkovic D., Linz W., Stasch J.P., Ahlbory K., Rosen R., Bohm M., and Nickenig G. Raloxifene improves endothelial dysfunction in hypertension by reduced oxidative stress and enhanced nitric oxide production. Circulation 105 (2002) 2083-2091
25. Yang D., Feletou M., Levens N., Zhang J.N., and Vanhoutte P.M. A diffusible substance(s) mediates endothelium-dependent contractions in the aorta of SHR. Hypertension 41 (2003) 143-148